

ASX ANNOUNCEMENT

16 January 2023

# Receipt of R&D Tax Incentive

Transformative, concussion management technology company, **HITIQ Limited** (ASX: **HIQ**) (**HITIQ** or the **Company)** is pleased to advise that it has received its Research & Development Tax Incentive (RDTI) for the year ended 30 June 2022.

The RDTI of $2,180,805, which was in line with the Company's estimate, has been applied against the RDTI funding provided by Keystone Group Investments Pty Ltd as announced on 15 June 2022.

**- ENDS –**

Authorised for release by the Board of HITIQ Limited.

**For more information, contact:**


Mike Vegar
**CEO & MD**
HITIQ Limited
investors@hitiq.com

Elvis Jurcevic
**Investor Relations**
+61 408 268 271
ej@hitiq.com


## About HITIQ

HITIQ Limited (ASX: **HIQ**) operates in the healthcare equipment sector, providing and further developing a transformative, end-to-end concussion management technology platform. This platform aims to provide a total concussion ecosystem whereby the Company's products support the identification, monitoring and management of sport related brain injury. HITIQ's product suite utilises high-end technology that will span multiple domains – from early detection and surveillance to assessment and rehabilitation technology tools.

HITIQ is targeting a growing worldwide concussion management market including elite and recreational sport, clinical practitioners, military, research, and combat sports. The Company's first commercial partner is the Australian Football League, with current strategy initiatives expanding commercially into Rugby League, Rugby Union, Ice Hockey, Lacrosse, MMA and American Football (particularly the NCAA). The market opportunity globally represents ~500k athletes within the elite market and ~10million in the consumer market.